GRUNELABS = INNOVATION
The objective of GrüneLabs is the production of special medicines that can treat neurological diseases and other pathologies.
We are located in Uruguay and Portugal
WHO WE ARE
GrüneLabs is a pharmaceutical laboratory which seeks innovation in the processing of botanical specialties for the production of medicines with high technology, for children, adult and veterinary uses.
The main reference in Latin America and the world about the studies of cannabis and other psychotropics, the doctor and researcher Elisaldo Carlini, died on Wednesday 16th at the age of 90.
Carlini was a global pioneer in research on the therapeutic properties of cannabis. His students benefited thousands of people suffering from diseases such as epilepsy, multiple sclerosis and others.
We combine biotechnology and pharmaceuticals to achieve high quality products.
The innovative merit of the project is the procurement of cannabis oils for the treatment of various diseases.
To generate an extract that serves as raw material for the development of medicinal products.
Meroflex is a highly standardized pharmaceutical product derived from two chemovars of Cannabis sativa, predominantly CBD in a ratio of 2: 1 to THC.
MEET OUR TEAM
João Paulo Rocha has expertise in designing and building complex high-tech but functional and profitable industrial structures for the pharmaceutical industry specialized in cannabis.
Currently under construction and subsequent management of another GruneLabs laboratory with a capacity 10 times higher than the previous one in Portugal, he spends his free time studying the benefits of the plant and the new technologies for cultivation, extraction and processing of pharmaceutical and cosmetic products.
One of the pioneering entrepreneurs in the medical cannabis industry in Uruguay. Partner and CEO of the Grunelabs Group.